Electrical Nerve Block for Amputation Pain
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02221934 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 21, 2014
Last Update Posted : November 22, 2022
|
Sponsor:
Neuros Medical, Inc.
Information provided by (Responsible Party):
Neuros Medical, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the clinical trial is to learn whether electrical nerve block via the Altius System is a safe and effective treatment for patients with post-amputation pain.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Post-Amputation Pain Phantom Limb Pain Residual Limb Pain Stump Pain | Device: Altius | Not Applicable |
The Altius System is an implanted device designed to electrically block nerve signals and alleviate pain. Use of this device may be associated with providing an effective, mechanism-based yet non-destructive, treatment for managing intractable limb pain in amputees. In a given patient, the Altius System will be deemed effective if treatment results in 50% reduction of pain score for more than 50% of all pain episodes.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 180 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | High-Frequency Nerve Block for Post-Amputation Pain: A Pivotal Study |
| Actual Study Start Date : | October 9, 2014 |
| Actual Primary Completion Date : | December 31, 2021 |
| Estimated Study Completion Date : | December 31, 2026 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Signal more likely to block nerve
Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
|
Device: Altius
Electrical signal |
|
Active Comparator: Signal less likely to block nerve
Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
|
Device: Altius
Electrical signal |
Primary Outcome Measures :
- Primary Effectiveness Endpoint: Reduction of Pain Level by 50% from Baseline [ Time Frame: 3 months post implant ]Demonstration of 50% reduction in a Numerical Rating Scale (NRS) pain score from pre-treatment to post-treatment for more than 50% of all pain episodes. Study success will be determined by a superiority test on the difference between responder rates in the Test group (those receiving the treatment) and Control group (those who do not receive treatment).
- Primary Safety Endpoint: Incidence of Reported and Adjudicated Serious Adverse Events [ Time Frame: From consent through 3 months post implant ]Incidence of all serious adverse events including serious adverse device events and unanticipated adverse device events.
Secondary Outcome Measures :
- Secondary Effectiveness: Pain Relief after 2 hours [ Time Frame: 12 months post implant ]Average percent change of pain intensity from before treatment, 30 minutes post treatment, and 2 hours post treatment
- Secondary Effectiveness: Pain Days per Week [ Time Frame: 12 months post implant ]Average number of pain days compared at Month 3, Month 6 and Month 12 to Baseline.
- Secondary Effectiveness: Pain Medication Use [ Time Frame: 12 months post implant ]Average morphine equivalent dose per day over two weeks compared at Month 3, Month 6 and Month 12 to Baseline.
- Secondary Effectiveness: Pain Interference to Activities of Daily Living (ADL [ Time Frame: 12 months post implant ]Brief Pain Inventory summary score compared at Month 3, Month 6 and Month 12 to Baseline.
- Secondary Effectiveness: Health-related quality of life (HR-QOL) [ Time Frame: 12 months post implant ]EQ-5D summary index, SF-12 physical component and mental component summary compared at Month 3, Month 6 and Month 12 to Baseline.
- Secondary Effectiveness: Patient Global Impression of Change (PGIC) [ Time Frame: 12 months post implant ]Comparison of Patient Global Impression of Change across the Month 3, Month 6 and Month 12 office visits
- Secondary Safety [ Time Frame: 12 months post implant ]Incidence of all Non-Serious Adverse Events, including Non-Serious Adverse Events, Non-Serious Adverse Device Events, and Unanticipated (Non-Serious) Adverse Device Events from the time of consent through 12 months post implant.
Other Outcome Measures:
- Exploratory Efficacy: Prosthetic Use [ Time Frame: 12 months post implant ]Average hours of prosthetic use per week averaged across two weeks compared at Month 3, Month 6 and Month 12 to Baseline.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Age ≥ 21 years old
- Unilateral amputated leg ≥ 12 months
- Chronic post amputation pain ≥ 6 months
- Pain episodes typically lasting ≥ 60 minutes
- Stable drug regimen ≥ 4 weeks
- No changes to medications or prosthesis for 3-month primary study period
Key Exclusion Criteria:
- Implanted with an active implantable medical device (i.e. pacemaker)
- Confounding source of pain that interferes with reporting of limb pain
- Uncontrolled diabetes
- Spasticity preventing full range of motion of involved side
- Extremely short stump; sits on end
- Untreated psychological condition (i.e. borderline personality)
- Condition requiring MRI studies or diathermy after device implant
- Life expectancy of less than 24 months
- Progressive neurological disease (i.e. multiple sclerosis)
- Subjects with active local or systemic infection or immunocompromised
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221934
Locations
Show 22 study locations
Sponsors and Collaborators
Neuros Medical, Inc.
Investigators
| Principal Investigator: | Leonardo Kapural, MD, PhD | Center for Clinical Research, Winston-Salem NC |
Additional Information:
Publications:
Publications:
| Responsible Party: | Neuros Medical, Inc. |
| ClinicalTrials.gov Identifier: | NCT02221934 |
| Other Study ID Numbers: |
003-0001 QUEST Trial ( Other Identifier: Neuros Medical ) |
| First Posted: | August 21, 2014 Key Record Dates |
| Last Update Posted: | November 22, 2022 |
| Last Verified: | November 2022 |
Keywords provided by Neuros Medical, Inc.:
|
Pain Chronic Amputation Phantom Pain Stump Pain |
Additional relevant MeSH terms:
|
Phantom Limb Perceptual Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain |